Editorial Policies

Focus and Scope

Annals of Pharma Research [ISSN: 2347-1956] is an International, open access, peer-reviewed, multidisciplinary journal. Its main goal is to act as catalyst in the Pharmaceutical, Medical and Biological sciences with updating scientific knowledge and e-distribution of literature to the scientific community by Open Access.

Annals of Pharma Research (ISSN: 2347- 1956)Â is an International, open access, peer-reviewed, multidisciplinary monthly journal. Its main goal is to act as catalyst in the pharmaceutical research with updating the scientific knowledge and e-distribution of scientific literature to the Pharmaceutical community by publishing valuable information and education resources.The journal widely includes multidisciplinary research findings in the fields of Pharmaceutical Sciences such as; Pharmaceutical Chemistry, Biopharmaceutics, Pharmaceutics, Pharmaceutical Technology, Medicinal Chemistry, Pharmaceutical Analysis, Quality Assurance, Pharmacology & Toxicology, Pharmacy Practice includes Hospital, Community & Clinical Pharmacy, Pharmacognosy, Pharmaceutical Microbiology & Biotechnology, Regulatory Affairs, Pharmaceutical Marketing Research, Medical Science and Alternative Medicines.

Section Policies

Articles

Open Submissions

Indexed

Peer Reviewed

Peer Review Process

Annals of Pharma Research publishes the finest peer reviewed research articles in the fields of chemical and life sciences on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility and elegance. IJCLS is a dedicated home for findings of exceptional significance from across the chemical and Life sciences. At the forefront the most exciting developments in the chemical and Life sciences, helping to define the important areas by publishing the most significant cutting edge research.

Initial manuscript evaluation

Editors make an initial evaluation of all manuscripts submitted to the journal. Manuscripts rejected at this stage typically are insufficiently original, have serious scientific flaws, or are outside the aims and scope of the journal. Those that meet the minimum criteria are passed on to at least one expert for review.

Authors of manuscripts rejected at this stage will be informed as soon as possible, usually within 1-2 weeks of receipt.

Peer Review Process:

Annals of Pharma Research employs rapid blind reviewing, where both the referee and author remain anonymous throughout the process.

Referee Selection:

Referees are matched to the paper according to their expertise.

Referee reports:

Referees are asked to evaluate whether the manuscript:

Is original
Is methodologically sound
Follows appropriate ethical guidelines
Has results which are clearly presented and support the conclusions
Correctly references previous relevant work
Is well written

Language correction is not part of the peer review process, but referees may suggest corrections to the manuscript.

Publication Frequency

Monthly

Open Access Policy

This journal provides immediate open access to its content on the principle that making research freely available to the public supports a greater global exchange of knowledge.

Archiving

This journal utilizes the LOCKSS system to create a distributed archiving system among participating libraries and permits those libraries to create permanent archives of the journal for purposes of preservation and restoration. More...

Copyright Policy

Annals of Pharma Research, its work and all published content is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Creative Commons License

Copyright without Restrictions

Annals of Pharma Research [ISSN: 2347-1956] allows the journal & author(s) to hold the copyright without restrictions and will retain publishing rights without restrictions.under following conditions: published source must be acknowledged and publisher's version/PDF may be used. If the author(s) intend(s) to republish their work in a secondary publication, the author(s) and editor(s) of the publications concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication

Policy of screening for plagiarism

Papers submitted to Annals of Pharma Research routinely screened plagiarism using Similarity Check / iThenticate plagiarism detection tools.

Publication Ethics and Malpractice Statement

The publication of article in Annals of Pharma Research [ISSN: 2347-1956] an essential building block in the development of a coherent and respected network of knowledge. It is a direct reflection of the quality of the work produced from the authors and the institutions that support them. Peer-reviewed articles support and embody the scientific method. It is highly recommended to agree upon standards of expected ethical commitment for all roles involved in the act of publishing: the author, the journal editor, the peer reviewer, the publisher and the society.

Annals of Pharma Research [ISSN: 2347-1956] Publisher takes its duties of responsibility over all stages of publishing extremely seriously and recognize our ethical and other responsibilities. We are dedicated to ensuring that advertising, reprint or other commercial revenue has no impact or influence on editorial decisions. In addition, publisher and Editorial Board will assist in communications with other journals and /or publishers where this is useful and necessary.

Duties of Authors

(These guidelines are based on existing Elsevier policies).

Reporting standards: Reports submitted by authors should be, accurate account of the work performed as well as objective discussion of its significance. Underlying data should be represented accurately in the paper. A paper should contain sufficient detail and references to permit others to replicate the work. Fraudulent or knowingly inaccurate statements constitute unethical behavior and are unacceptable. Review and professional publication articles should also be accurate and objective, and editorial works should be clearly identified as such.

Data access and retention: Authors may be asked to provide the raw data in connection with a paper for editorial review, and should be prepared to provide public access to such data, if practicable, and should in any event be prepared to retain such data for a reasonable time after publication.

Originality and plagiarism: The authors should ensure that they have written entirely original works, and if the authors have used the work and/or words of others that this has been appropriately cited or quoted. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable.

Multiple, redundant or concurrent publication: An author should not in general publish manuscripts describing essentially the same research in more than one journal or primary publication. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable. In general, an author should not submit for consideration in another journal a previously published paper. Publication of some kinds of articles (e.g. clinical guidelines, translations) in more than one journal is sometimes justifiable, provided certain conditions are met. The authors and editors of the journals concerned must agree to the secondary publication, which must reflect the same data and interpretation of the primary document. The primary reference must be cited in the secondary publication.

Acknowledgement of sources: Proper acknowledgment of the work of others must always be given. Authors should cite publications that have been influential in determining the nature of the reported work. Information obtained privately, as in conversation, correspondence, or discussion with third parties, must not be used or reported without explicit, written permission from the source. Information obtained in the course of confidential services, such as refereeing manuscripts or grant applications, must not be used without the explicit written permission of the author of the work involved in these services.

Authorship of the paper: Authorship should be limited to those who have made a significant contribution to the conception, design, execution, or interpretation of the reported study. All those who have made significant contributions should be listed as co-authors. Where there are others who have participated in certain substantive aspects of the research project, they should be acknowledged or listed as contributors. The corresponding author should ensure that all appropriate co-authors and no inappropriate co-authors are included on the paper, and that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

Hazards and human or animal subjects: If the work involves chemicals, procedures or equipment that have any unusual hazards inherent in their use, the author must clearly identify these in the manuscript. If the work involves the use of animal or human subjects, the author should ensure that the manuscript contains a statement that all procedures were performed in compliance with relevant laws and institutional guidelines and that the appropriate institutional committee(s) has approved them. Authors should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

Disclosure and conflicts of interest: All authors should disclose in their manuscript any financial or other substantive conflict of interest that might be construed to influence the results or interpretation of their manuscript. All sources of financial support for the project should be disclosed. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest stage possible.

Fundamental errors in published works: When an author discovers a significant error or inaccuracy in his/her own published work, it is the authorís obligation to promptly notify the journal editor or publisher and cooperate with the editor to retract or correct the paper. If the editor or the publisher learns from a third party that a published work contains a significant error, it is the obligation of the author to promptly retract or correct the paper or provide evidence to the editor of the correctness of the original paper.

Role of Editorial Team

These guidelines are based on existing Elsevier policies and copies Best Practice Guidelines for Journal Editors.

Publication decisions: The editor of a peer-reviewed journal Annals of PlantSciences [ISSN: 2287-688X] is responsible for deciding which of the articles submitted to the journal should be published. The validation of the work in question and its importance to researchers and readers must always drive such decisions. The editor may be guided by the policies of the journal's editorial board and constrained by such legal requirements as shall then be in force regarding libel, copyright infringement and plagiarism. The editor may confer with other editors or reviewers in making this decision.

Fair play: An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political philosophy of the authors.

Confidentiality: The editor and any editorial staff must not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, as appropriate.

Disclosure and conflicts of interest: Unpublished materials disclosed in a submitted manuscript must not be used in an editor's own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from considering manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) institutions connected to the papers. Editors should require all contributors to disclose relevant competing interests and publish corrections if competing interests are revealed after publication. If needed, other appropriate action should be taken, such as the publication of a retraction or expression of concern.

Involvement and cooperation in investigations: An editor should take reasonably responsive measures when ethical complaints have been presented concerning a submitted manuscript or published paper, in conjunction with the publisher (or society). Such measures will generally include contacting the author of the manuscript or paper and giving due consideration of the respective complaint or claims made, but may also include further communications to the relevant institutions and research bodies, and if the complaint is upheld, the publication of a correction, retraction, expression of concern, or other note, as may be relevant. Every reported act of unethical publishing behavior must be looked into, even if it is discovered years after publication.

Role of Reviewer

(These guidelines are based on existing Elsevier policies and COPE Best Practice Guidelines for Journal Editors).

Contribution to editorial decisions: Peer review assists the editor in making editorial decisions and through the editorial communications with the author may also assist the author in improving the paper. Peer review is an essential component of formal scholarly communication, and lies at the heart of the scientific method. Elsevier shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.

Promptness: Any selected referee who feels unqualified to review the research reported in a manuscript or knows that its prompt review will be impossible should notify the editor and excuse himself from the review process.

Confidentiality: Any manuscripts received for review must be treated as confidential documents. They must not be shown to or discussed with others except as authorized by the editor.

Standards of objectivity: Reviews should be conducted objectively. Personal criticism of the author is inappropriate. Referees should express their views clearly with supporting arguments.

Acknowledgement of sources: Reviewers should identify relevant published work that has not been cited by the authors. Any statement that an observation, derivation, or argument had been previously reported should be accompanied by the relevant citation. A reviewer should also call to the editor's attention any substantial similarity or overlap between the manuscript under consideration and any other published paper of which they have personal knowledge.

Disclosure and conflict of interest: Unpublished materials disclosed in a submitted manuscript must not be used in a reviewerís own research without the express written consent of the author. Privileged information or ideas obtained through peer review must be kept confidential and not used for personal advantage. Reviewers should not consider manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the papers.

Retraction Policy

Annals of Pharma Research [ISSN: 2347-1956] prioritize the importance of integrity and fulfillment of the scholarly record. The historic record of published research articles shall remain available and unaltered as far as possible. However, circumstances may arise where a paper got published based on misconduct or honest error. Editors certainly guide the review process with much care, but it remains notoriously difficult to detect all occurrences of misconduct or error. For this reason it may become necessary to correct the scholarly record. The decision to alter the record should not be taken lightly. Action taken depends on the individual case and can take the form of

Expression of Concern
Correction (Erratum or Corrigendum)
Retraction
Removal

The purpose of the action is to correct the literature and to alert readers. It is not intended to punish the author(s).

The responsibility of guiding an investigation of misconduct or honest error is with the editor of the journal concerned. Authors and reviewers will take part in the investigation. The editor will decide on the form to best correct the scholarly record. Guiding principles are COPE's Retraction Guidelines and other accepted scholarly principles.

Minor errors that do not affect the integrity of the metadata or a reader's ability to understand an article and that do not involve a scientific error or omission are corrected such that the original article is replaced with the corrected version. If requested action originates from an author, final action will be according to decision made by Editors and Editorial Panel Members

Disclaimer

The Publisher and Editors cannot be held responsible for any type of error OR any consequences arising from the use of information in this web site of journal, the view and opinion expressed by the authors do not necessarily reflect those of the Publisher/Association and Editors, neither does the publication of advertisements constitute any endorsement by the Publisher/ Association and Editors of the products advertised. The authors are responsible for the contents appeared in their published manuscripts.

OPEN ACCESS STATEMENT

The Journal Annals of Pharma Research [ISSN: 2347-1956] provides immediate open access to its content. Full-text access to scientific articles of the journal is presented on the Annals of Pharma Research website (https://www.annalsofpharmaresearch.com/). The Journal Annals of Pharma Research an open access journal, which means all its content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.

Annals of Pharma Research Theory & Law strongly support and comply with the DOAJ definition of open access. The published contents have no embargo period, are available without registration.